All In Biotech

Drug Trial Radar · NCT05084989

Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)

A Randomized, Blinded, Two-part, Phase II Trial to Evaluate the Safety and Immunogenicity of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) in Adults 18 Years and Older

Last checked: Nov 19, 2026Latest source record: Feb 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 948 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

948

Actual

Start

Jan 31, 2022

Primary completion

Aug 18, 2022

Study completion Feb 9, 2023

Sponsor

Sponsor type
Industry
First posted
Oct 20, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Part 1: Primary Vaccination in Adults Part 1 will evaluate the safety and immunogenicity of the recombinant two component COVID-19 vaccine (CHO cell) (ReCOV for short) in adults aged 18 years and older, when administered as 2 intramuscular doses, 21 days apart. Part 2: Booster Vaccination in Adults Part 2 will evaluate the immunogenicity and safety and of one booster dose of ReCOV in adult participants who have received primary vaccination with 2 doses of an inactivated COVID-19 vaccine (CoronaVac®). COMIRNATY®, an mRNA COVID-19 vaccine will be used as the active control.

Conditions

  • COVID-19

Interventions

  • Part1:Recombinant two-component COVID-19 vaccine (CHO cell)Biological

    2 doses. Before reconstitution:Lyophilized powder for reconstitution in single-use vials; After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter; Unite Does Strengths: 40ug/vial; Does Volume: 0.5ml/dose Routine of administration: Intramuscular (IM) injection

  • Part1: PlaceboBiological

    2 doses. Before reconstitution: Lyophilized powder for reconstitution in single-use vials; After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter; Unite Does Strengths: Not Applicable; Does Volume: 0.5ml/dose; Routine of administration: IM injection;

  • Part2: Recombinant two-component COVID-19 vaccine (CHO cell)Biological

    1 dose.Before reconstitution:Lyophilized powder for reconstitution in single-use vials; After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter; Unite Does Strengths: 40ug/vial; Does Volume: 0.5ml/dose Routine of administrati

  • Part2: COVID-19 Vaccine, mRNABiological

    1 dose. Intramuscular injection, 30 μg/0.3 mL.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part1, Primary SafetyTime frame: Day 7 after first dose and up to Day 28 after second dose
  2. Part1, Primary immunogenicityTime frame: 14 days after 2 doses vaccination
  3. Part2, Primary immunogenicityTime frame: 14 days after 2 doses vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Health Centrum

    Roxas City, Philippines

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.